Logout
If you want to log out click in LogOut
The Wnt beta Catenin signaling pathway (also referred to as Wnt/β-Catenin signaling pathway) is a highly conserved molecular signaling cascade that regulates cell proliferation, differentiation, migration, and survival.
It plays a fundamental role in embryonic development, tissue homeostasis, and regeneration, and remains tightly controlled in adult tissues.
In the canonical Wnt pathway, extracellular Wnt ligands trigger intracellular signaling events that stabilize β-catenin, allowing it to translocate into the nucleus and activate transcriptional programs controlling cell fate and metabolism.
Dysregulation of Wnt/β-catenin signaling is strongly associated with cancer, fibrosis, metabolic disorders, and stem cell dysfunction.
Wnt/β-catenin pathway activity can be efficiently assessed by measuring gene expression of core regulators, downstream targets, and pathway-specific biomarker signatures.
Wnt/β-catenin signaling pathway biomarker list
View the genes included in our Wnt/β-catenin pathway qPCR arrays.
The pathway operates through a tightly regulated ON / OFF switch:
OFF state
β-catenin is continuously phosphorylated and degraded by the destruction complex, preventing transcriptional activation.
ON state
Wnt ligand binding inactivates the destruction complex, allowing β-catenin stabilization and nuclear signaling.
This dynamic balance ensures accurate cellular responses to environmental and developmental cues.
Canonical Wnt signaling is initiated when Wnt ligands bind to Frizzled receptors and co-receptors LRP5/6 at the cell surface. This interaction inhibits the β-catenin destruction complex, allowing β-catenin accumulation in the cytoplasm.
Once stabilized, β-catenin translocates to the nucleus, where it interacts with TCF/LEF transcription factors to activate genes involved in:
Core molecular components
• Wnt ligands – extracellular signaling proteins
• Frizzled receptors & LRP5/6 – signal reception at the membrane
• β-catenin – central transcriptional effector
• Destruction complex (APC, AXIN, GSK-3β, CK1) – regulates β-catenin degradation in the absence of Wnt signaling
Aberrant activation or suppression of Wnt/β-catenin signaling contributes to numerous pathological conditions:
Cancer: Hyperactivation promotes uncontrolled proliferation, tumor initiation, progression, and therapeutic resistance
(Common in colorectal, breast, pancreatic and liver cancers).
Fibrosis: Sustained signaling drives fibroblast activation and extracellular matrix deposition
Bone disorders: Impaired signaling alters bone remodeling and density, contributing to osteoporosis.
Neurological diseases: Dysregulation affects neurogenesis and synaptic plasticity, linked to neurodegenerative disorders.
Metabolic diseases: Altered Wnt/β-catenin activity disrupts adipogenesis, glucose metabolism and energy balance.
The Wnt/β-catenin signaling pathway interacts extensively with other major signaling networks:
This crosstalk highlights the pathway’s central role in complex biological systems.
At AnyGenes®, we provide high-performance qPCR arrays and customizable SignArrays® dedicated to Wnt/β-catenin pathway analysis.
Our solutions enable researchers to:
What can be analyzed?
Scientific data is only as powerful as the analysis behind it.
AnyGenes® provides a dedicated data analysis tool specifically developed for SignArrays® pathway panels.
What does it allow you to do?
Developed on Excel (compatible with 2007+), the software is user-friendly and requires no advanced bioinformatics skills.
Customize your own signaling pathways (SignArrays®) with the factors of your choice!
Simply download and complete our Personalized SignArrays® information file
and send it at
[email protected]
to initiate your project.
It is activated by Wnt ligands binding to Frizzled and LRP5/6 receptors, leading to β-catenin stabilization and nuclear transcriptional activation.
Its dysregulation promotes uncontrolled proliferation, stemness, metastasis and therapy resistance.
Key genes include CTNNB1 (β-catenin), APC, AXIN1/2, GSK3B, LRP5/6, TCF7 and LEF1.
By measuring expression of pathway regulators and downstream targets using targeted gene expression approaches such as qPCR pathway arrays.
| Signaling Pathways | Product ref | Informations |
|---|---|---|
Wntβ-catenin Signaling Pathway | WNTB1H1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
Wntβ-catenin Signaling Pathway | WNTB1M1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
Wntβ-catenin Signaling Pathway | ******* |
Biomarker list in progress. |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
Wntβ-catenin Signaling Pathway | ******* |
Biomarker list in progress. |
Looking for more answers? Visit our Help & FAQ section to find detailed informations about our products, services, and technical support.
1. Haseeb M et al. Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics. Cells. (2019)3;8(11).
2. Lecarpentier Y et al. Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers. Front Oncol. (2019)18;9:1248.
3. Zhong Z et Virshup DM. Wnt signaling and drug resistance in cancer. Mol Pharmacol. (2019)1.
4. Mo Y et al. The role of Wnt signaling pathway in tumor metabolic reprogramming. J Cancer. (2019)9;10(16):3789-3797.
5. Ram Makena M et al. Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance. Int J Mol Sci. (2019)30;20(17).
6. Ng LF et al. WNT Signaling in Disease. Cells. (2019)3;8(8).